Efficacy of erlotinib and its effects on the quality of life of older patients with epidermal growth factor receptor‐mutant non‐small cell lung cancer: A prospective, multicenter, dose‐modification study-Reference-Cited by-同舟云学术

Efficacy of erlotinib and its effects on the quality of life of older patients with epidermal growth factor receptor‐mutant non‐small cell lung cancer: A prospective, multicenter, dose‐modification study

Published:2021-08-10 Issue:10 Volume:21 Page:881-886
ISSN:1444-1586
Container-title:Geriatrics & Gerontology International
language:en
Short-container-title:Geriatr. Gerontol. Int.

Author:

Tsubata Yukari¹^ORCID,Masuda Takeshi²,Hamai Kosuke³,Taniwaki Masaya⁴,Tanino Akari¹,Hotta Takamasa¹,Hamaguchi Megumi¹,Hamaguchi Shunichi¹,Yamasaki Masahiro⁴,Ishikawa Nobuhisa⁵,Fujitaka Kazunori²,Sutani Akihisa⁵,Isobe Takeshi¹

Affiliation:

1. Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine Shimane University Faculty of Medicine Izumo Japan

2. Department of Respiratory Internal Medicine Hiroshima University Hospital Hiroshima Japan

3. Department of Respiratory Medicine Hiroshima Prefectural Hospital Hiroshima Japan

4. Department of Respiratory Medicine Hiroshima Red Cross Hospital and Atomic‐bomb Survivors Hospital Hiroshima Japan

5. Respiratory Medicine SUTANI Clinic Izumo Japan

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ggi.14243

Reference21 articles.

1. National Cancer Center Japan.Cancer information service. [Cited 22 Mar 2021.] Available from URL:https://ganjoho.jp/reg_stat/index.html.

2. First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non–Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: NEJ 003 Study

3. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)

4. Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations

5. Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation–Positive Non–Small Cell Lung Cancer

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multifaceted role of erlotinib in various cancer: nanotechnology intervention, patent landscape, and advancements in clinical trials;Medical Oncology;2024-06-12

2. Patient Age andEGFR-positive Non-small Cell Lung Cancer: A Multicenter Retrospective Study;Anticancer Research;2024-03-27

3. Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP);Lung Cancer;2023-12

4. Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?;Expert Review of Anticancer Therapy;2022-11-24